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Despite decades of concerted epidemiological research, relatively little is known about the etiology of prostate cancer. As
genome-wide association studies have identified numerous genetic variants, so metabolomic profiling of blood and other tis-
sues represents an agnostic, “broad-spectrum” approach for examining potential metabolic biomarkers of prostate cancer
risk. To this end, we conducted a prospective analysis of prostate cancer within the Alpha-Tocopherol, Beta-Carotene Cancer
Prevention Study cohort based on 200 cases (100 aggressive) and 200 controls (age- and blood collection date-matched) with
fasting serum collected up to 20 years prior to case diagnoses. Ultrahigh performance liquid chromatography/mass spectros-
copy and gas chromatography/mass spectroscopy identified 626 compounds detected in >95% of the men and the odds ratio
per 1-standard deviation increase in log-metabolite levels and risk were estimated using conditional logistic regression. We
observed strong inverse associations between energy and lipid metabolites and aggressive cancer (p50.018 and p50.041,
respectively, for chemical class over-representation). Inositol-1-phosphate showed the strongest association (OR50.56, 95%
CI50.39–0.81, p50.002) and glycerophospholipids and fatty acids were heavily represented; e.g., oleoyl-linoleoyl-
glycerophosphoinositol (OR50.64, p50.004), 1-stearoylglycerophosphoglycerol (OR=0.65, p50.025), stearate (OR=0.65,
p50.010) and docosadienoate (OR50.66, p50.014). Both alpha-ketoglutarate and citrate were associated with aggressive
disease risk (OR50.69, 95% CI50.51–0.94, p50.02; OR50.69, 95% CI50.50–0.95, p50.02), as were elevated thyroxine
and trimethylamine oxide (OR51.65, 95% CI51.08–2.54, p50.021; and OR51.36, 95% CI51.02–1.81, p50.039). Serum
PSA adjustment did not alter the findings. Our data reveal several metabolomic leads that may have pathophysiological rele-
vance to prostate carcinogenesis and should be examined through additional research.
Despite being the most commonly diagnosed malignancy and
the second leading cause of cancer death among men in
most developed populations,1 hypothesis-driven research has
yet to elucidate established modifiable risk factors for prostate
cancer. Similar to agnostic methods such as genome-wide
association studies that have successfully identified novel bio-
logical pathways relevant to prostate and other cancers,2
metabolomic technologies measuring a wide array of low
molecular weight biochemicals in blood and other tissues are
a powerful new tool that may help identify compounds rele-
vant to cancer etiology, early detection or progression.3,4 For
example, metabolomic profiles of tissue, urine and blood
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from men with prostate cancer have been examined, includ-
ing by disease aggressiveness.5,6 Our previous serum metabo-
lomic analysis of prostate cancer risk in 74 nested case-
control pairs with up to 23 years of follow-up within the
Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC)
Study of male smokers found strong inverse risk signals for
circulating 1-stearoylglycerol (or 1-monostearin), glycerol and
alpha-ketoglutarate along with several other lipid metabolites,
supporting a role for lipid and energy dysregulation in pros-
tate carcinogenesis.7 The associations persisted among cases
diagnosed >5 years after blood collection and appeared
stronger for cases that were aggressive at diagnosis. The novel
findings were based on a relatively small sample, however
and required reexamination. We therefore endeavored in the
present study to replicate the initial results in a larger pro-
spective study sample.
Material and Methods
Study population
Details of the Alpha-Tocopherol, Beta-Carotene Cancer Pre-
vention (ATBC) Study have been described.8 Male Caucasian
50–69 year old smokers from southwestern Finland
(n5 29,133) were recruited from 1985 to 1988. They were
assigned to one of the following intervention groups based
on a 2 3 2 factorial trial design: (i) a-tocopherol (dl-a-toco-
pheryl-acetate, 50 mg/day), (ii) b-carotene (20 mg/day), (iii)
both supplements or (iv) placebo. Participants took the study
capsules for 5–8 years (median 6.1 years) through April 30,
1993 or until they left the trial. Questionnaires about general
risk factors, smoking and medical history as well as a vali-
dated food-frequency questionnaire were completed at entry,
height and weight were measured and serum was collected
(after an overnight fast) protected from light and stored at
270 8C until assayed. Written informed consent was
obtained from all participants and the trial was approved by
institutional review boards at both the Finnish National Pub-
lic Health Institute and the US National Cancer Institute.
Case identification and control selection
The present analysis includes 200 confirmed cases of incident
prostate adenocarcinoma (ICD-9 185) matched 1:1 with con-
trols on age (61 year) and date of baseline blood collection
(6 30 days). These cases and controls were independent of
our original study,7 having no overlap. To enable us to exam-
ine aggressive cases separately and to examine associations
stratifying by time between blood collection and diagnosis,
cases were randomly selected such that 25 nonaggressive and
25 aggressive cases were sampled from each of four periods
between blood collection and diagnosis: <5 years, 5-<10
years, 10-<15 years and 15-20 years. Aggressive cases were
defined as TNM stage III-IV, AJCC stage 3 or Gleason sum
8. Only two cases (stage 2) were included as “aggressive”
based solely on a high Gleason sum.
Laboratory analyses
Serum metabolomic profiling was conducted at Metabolon
(Durham, N.C.) using ultrahigh performance liquid chroma-
tography/mass spectroscopy and gas chromatography/mass
spectroscopy. Sixteen batches of case-control pairs and qual-
ity control (QC) replicate samples (8%) were analyzed. Raw
data were extracted, peak-identified and QC processed on the
assay platform as previously described.9,10 After excluding
metabolites that had >20 (5%) missing values, 626 identified
compounds remained for analysis. Based on existing litera-
ture, metabolites were categorized as eight mutually exclusive
chemical classes (amino acids, carbohydrates, cofactors and
vitamins, energy metabolites, lipids, nucleotides, peptides and
xenobiotics). The median and interquartile range of the CV%
across the metabolites was 9% (4–20%). These CVs are simi-
lar to those previously observed for blood samples analyzed
by the same laboratory.11
Serum total prostate specific antigen (PSA) concentration
was measured in the clinical chemistry laboratory of Dr.
Alan Remaley in the NIH Clinical Center. Each batch
included blinded duplicate QC samples, with the CVs rang-
ing from 5 to 10%.
Statistical analyses
To standardize for batch variability, the signal strength of each
metabolite was divided by the median value of participants in a
given batch; these normalized levels were then log-transformed
and missing values were assigned the minimum nonmissing
value. We estimated the association between log-metabolite lev-
els and prostate cancer by conditional logistic regression. In
addition to the matching factors, the following variables were
evaluated as potential confounders: trial treatment group, fam-
ily history of prostate cancer, history of benign prostatic hyper-
plasia (BPH), physical activity, body mass index, smoking
(cigarettes per day), serum total and HDL cholesterol, serum
retinol and serum a-tocopherol. Inclusion of any of these
What’s new?
Prostate cancer is the second most common cancer in men, yet few modifiable risk factors are known. A window to the study
of modifiable risk factors is the metabolome, with prospective metabolomic serum profiling being a promising new investiga-
tive approach. In prostate cancer, use of this approach had resulted in the identification of numerous circulating lipids associ-
ated with risk of aggressive disease. Here, the authors report inverse associations between aggressive disease and energy
and lipid metabolites, including alpha-ketoglutarate, citrate, inositol-1-phosphate and several glycerophospholipids and fatty
acids. Some of the metabolites may be relevant to prostate cancer development and progression.
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variables in the model did not change the effect of any metabo-
lite by 10% or more. Thus, our final model is conditioned on
the matching factors only. Subgroup analyses were conducted
based on trial a-tocopherol and b-carotene supplementation
(yes/no for each), smoking intensity (split at 20 cigarettes daily)
and BMI, serum total and HDL cholesterol (all based on
medians). The threshold for statistical significance in our pri-
mary analysis is p5 0.00008, based on a Bonferroni correction
for 626 tests; the threshold is 0.003 for the most significant
metabolites in the main analysis, based on correction for 170
tests. It should be noted that this is a highly conservative (i.e.,
stringent) threshold because of intercorrelation among many of
the metabolites. Key findings of this analysis were meta-
analyzed with data from our initial study in this cohort7 using a
random effects modeling approach. We evaluated the associa-
tion between chemical classes of metabolites and prostate can-
cer using Gene Set Analysis (GSA) as described in detail by
Efron and Tibshirani,12 a potentially more robust and powerful
test than the Gene Set Enrichment Analysis described by Subra-
manian et al.13 Letting {z1, . . ., zs}be the Z values from testing
the S metabolites in a pathway, GSA evaluates the “maxmean”
statistic max (-z1,-z2), where -z1(-z2) is the average of all
positive (negative) values and calculates the p-values by 10,000
permutations.
All analyses were performed using SAS version 9.1.3 (SAS
Institute, Cary, N.C.), with the exception of the GSA, which
was conducted using R; all statistical tests were 2-sided.
Results
Characteristics of the study population are shown in Table 1.
Only serum retinol and total PSA differed significantly
between cases and controls, both being higher among cases.
Serum metabolites associated with risk of total, nonaggres-
sive and aggressive prostate cancer at a p< 0.05 level of statisti-
cal significance are shown sorted by chemical class and then by
p values in Tables (2–4) (none achieved p5 0.00008 level of sig-
nificance). Although not found for all cases combined or for
nonaggressive disease (Tables 2 and 3, respectively), we
observed strong risk associations between the energy and lipid
metabolite chemical classes and aggressive cancer, with both
being statistically significantly over-represented among our top
metabolites (Table 4, energy p5 0.018, lipids p5 0.041). With
the exception of erucoyl-sphingomyelin (OR5 1.53) and trime-
thylamine oxide (TMAO; OR 1.36), all other lipids were inver-
sely related to aggressive prostate cancer (Table 4). Inositol-1-
phosphate showed the strongest association (OR5 0.56, 95%
CI-0.39 – 0.81, p5 0.002), although glycerophospholipids (e.g.,
oleoyl-linoleoyl-glycerophosphoinositol and 1-stearoylglycero-
phosphoglycerol) and fatty acids (e.g., stearate and docosadie-
noate) were heavily represented. The lipid signal for overall
prostate cancer was weaker (chemical class test, p5 0.27; Table
2). The data in Tables (2–4) were not materially altered by
adjustment for serum total PSA, total cholesterol or retinol
(data not shown). Mutual adjustment for each other metabolite
led to relatively little overall attenuation of the ORs, although
some attenuation was evident when adjusting within chemical
classes (e.g., within lipids, stearate did attenuate the ORs for
many of the other fatty acids), while for some metabolites, asso-
ciations were strengthened (data not shown). A heat-map of
the aggressive prostate cancer metabolite intercorrelations
appears in Figure 1. Higher positive correlations were seen
among fatty acids and glycerophospholipids and PSA was
weakly correlated with the metabolites.
Of the metabolites most strongly associated with prostate
cancer in our initial study,7 the association between alpha-
ketoglutarate and aggressive prostate cancer replicated in the
present data (OR5 0.69, 95% CI-0.51 – 0.94, p5 0.02, Table
4). Another TCA cycle (i.e., citric acid or Krebs cycle) metab-
olite, citrate, was similarly but independently associated with
aggressive cancer risk (OR5 0.69; Table 4).
Even though we identified a large number of glycerophos-
pholipids and long chain fatty acids (LCFA) among the top
metabolites, 1-stearoylglycerol and glycerol (i.e., the two other
top signals from our prior study7) specifically were not asso-
ciated with prostate cancer risk in the present analysis
Table 1. Selected characteristics1 of the cases and controls
Controls Cases p-Value
N 200 200
Age (years) 59.3 59.4 Matched
Height (cm) 173 173 0.94
Weight (kg) 78.1 80.0 0.29
BMI (kg/m2) 26.0 26.6 0.18
Serum total cholesterol (mmol/L) 6.2 6.1 0.89
Serum a-tocopherol (mg/L) 11.8 11.6 0.33
Serum b-carotene (lg/L) 200 201 0.82
Serum retinol (lg/L) 587 611 0.02
Serum total PSA (ng/mL) 1.4 8.0 <0.0001
Cigarettes per day 19.4 19.3 0.87
Years of cigarette smoking 37.5 37.5 0.81
Family history of prostate cancer (%) 3.5 5.8 0.36
Physically active (%) 19.0 13.5 0.14
Dietary intake per day
Total energy (kcal) 2,667 2,662 0.96
Fruit (g) 216 205 0.52
Vegetables (g) 293 289 0.54
Red meat (g) 70.5 70.7 0.85
Alcohol (ethanol, g) 17.4 16.8 0.53
Supplement use
Vitamin A (%) 10.5 11.0 0.87
Vitamin D (%) 7.0 7.0 1.0
Calcium (%) 13.5 13.0 0.88
1Values are means unless otherwise indicated. All characteristics are
from the baseline questionnaire except family history, which was
collected during follow-up and is available for 264 men in this
analysis.
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(1-stearoylglycerol: OR5 1.03, 95% CI5 0.84–1.26, p5 0.79;
glycerol: OR5 0.96, 95% CI5 0.78–1.19, p5 0.71), with no
difference based on disease aggressiveness (data not shown).
Meta-analysis with our prior data also showed nonstatistically
significant inverse associations for overall prostate cancer: 1-
stearoylglycerol OR5 0.61, 95% CI5 0.21–1.79, p5 0.37;
glycerol OR5 0.77, 95% CI5 0.45–1.31, p5 0.33. Stratifying
our cases and their controls by the median time from serum
collection to diagnosis revealed more abundant glycerophos-
pholipid, sphingolipid and steroid hormone metabolites
inversely associated with aggressive prostate cancer diagnosed
within 10 years of serum collection, whereas medium chain
fatty acid (MCFA), LCFA and polyunsaturated fatty acid
(PUFA) metabolites were prominently and inversely associ-
ated in serum sampled from cases 10–20 years prior to diag-
nosis (data not shown). We observed no statistically
significant interaction between any of the 34 metabolites
associated with aggressive prostate cancer at p< 0.05 and the
following factors: the ATBC trial a-tocopherol or b-carotene
supplementation, BMI, cigarettes per day and serum total or
HDL cholesterol.
We found other notable, biologically relevant metabolite sig-
nals for prostate cancer. For aggressive disease, elevated thyro-
xine and TMAO were associated with higher risk: respectively,
OR5 1.65, 95% CI5 1.08 – 2.54, p5 0.021; and OR5 1.36,
95% CI5 1.02 – 1.81, p5 0.039. Metabolites associated with
nonaggressive cancers were nucleotides (2’-deoxyuridine and
adenosine 50-monophosphate (AMP): OR5 1.81, CI5 1.15 –
2.85, p5 0.010; and, OR5 1.50, CI5 1.032 2.16, p5 0.032,
respectively; p5 0.03 for nucleotide class), two steroid hor-
mones (11-dehydrocorticosterone and 21-hydroxypregnenolone
monosulfate: OR5 0.62, CI5 0.442 0.88, p5 0.0069; and
OR5 1.46, CI5 1.032 2.06, p5 0.034, respectively) and two
tobacco metabolites (cotinine and hydroxycotinine: OR5 0.59,
CI5 0.382 0.90, p5 0.014; and, OR5 0.67, CI5 0.472 0.96,
p5 0.029, respectively). It should also be noted that we did not
observe a positive risk association for the branched-chain
amino acids leucine, isoleucine and valine (data not shown), as
was recently reported for pancreatic cancer risk.14
Discussion
The present metabolomics analysis reveals associations
between aggressive prostate cancer and a large number serum
glycerophospholipids, LCFAs, PUFAs and TCA cycle com-
pounds, consistent with our recent preliminary data.7 Specifi-
cally, we replicated the original inverse association with
alpha-ketoglutarate (meta-analysis of the two sets reveals
alpha-ketoglutarate as the top metabolite associated with
aggressive disease: OR5 0.62, 95% CI5 0.46 – 0.82,
p5 0.0009) and identified several additional biologically rele-
vant diacyl-glycerophospholipids. These findings were inde-
pendent of BPH and serum total PSA, as evidenced by the low
Figure 1. Heat map of correlation coefficients among metabolites associated with aggressive prostate cancer.
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PSA-metabolite correlations and the lack of metabolite associa-
tion attenuation upon model adjustment for PSA or BPH.
Other than our initial investigation,7 this may be the only
report of a prospective metabolomics profiling study of pros-
tate cancer risk having long follow-up. Cross-sectional clinical
studies recently reviewed5,6 have primarily focused on metab-
olomic profiles of tumor tissue (primaries and metastases;
biopsies and prostatectomies) and urine in men with prostate
cancer. Although a large number of metabolites were detected
in relation to disease aggressiveness, metastases and biochem-
ical recurrence, evidence to support the associations with
increased glycerophospholipids, cholines and sarcosine and
decreased citrate and polyamines is more preponderant
(albeit, with inconsistent findings).6 These data do in fact
indicate that metabolite associations vary by cancer aggres-
siveness, mostly defined by stage at diagnosis, and we might
expect the serologic molecular patterns for aggressive and
advanced disease to be more similar to prostate cancer cases
profiled at the time of diagnosis than to early, nonaggressive
cancers. For example, we did identify several glycerophospho-
lipids and citrate as being inversely associated with aggressive
disease. Studies of serial prospective metabolomic profiles
leading up to clinical diagnosis will be useful in this regard.
The strong association signals for lipids and TCA cycle
members are consistent with current knowledge from abun-
dant basic research regarding cancer cell metabolic changes
related to energy, biosynthetic capacity and cell signaling.15–18
That rapidly proliferating malignant cells derive much of
their energy requirements from cytosolic anaerobic glycolysis,
possibly in response to hypoxic intra-tumor conditions, was
Table 2. Serum metabolites associated with overall prostate cancer (p<0.05)
Metabolite Subpathway
Odds
Ratio1 95% CI p-Value
p for
Chemical
Class
Lipids
3-Hydroxylaurate Fatty acid, monohydroxy 0.78 0.6320.96 0.0169 0.27
Oleoyl-linoleoyl-glycerophosphoinositol Glycerophospholipid 0.81 0.6521.00 0.0462
Erucoyl-sphingomyelin Sphingolipid metabolism 1.35 1.0721.70 0.0101
Stearoyl-arachidonoyl-
glycerophosphoethanolamine
Glycerophospholipid 0.76 0.6120.94 0.0109
Palmitoyl-linoleoyl-glycerophosphocholine Glycerophospholipid 0.78 0.6420.96 0.0166
Glycolithocholate sulfate Secondary bile acid metabolism 1.28 1.0421.57 0.0181
Docosadienoate (22:2n6) LCFA; polyunsaturated fatty acid 0.77 0.6220.96 0.0220
Inositol-1-phosphate (I1P) Inositol metabolism 0.77 0.6220.97 0.0231
Stearoyl-linoleoyl-
glycerophosphoethanolamine
Glycerophospholipid 0.80 0.6620.98 0.0329
3-Hydroxydecanoate Fatty acid, monohydroxy 0.80 0.6520.98 0.0335
Stearoyl-linoleoyl-glycerophosphocholine Glycerophospholipid 0.82 0.6720.99 0.0382
16a-Hydroxy-DHEA 3-sulfate Sterol/steroid 0.81 0.6621.00 0.0469
Tauro-beta-muricholate Primary bile acid metaolism 0.80 0.6421.00 0.0481
Amino Acids
4-Imidazoleacetate Histidine metabolism 1.33 1.0821.63 0.0074 0.40
Phenylpyruvate Phenylalanine and tyrosine metabolism 1.28 1.0321.57 0.0227
Beta-hydroxyisovalerate Valine, leucine and isoleucine metabolism 1.26 1.0221.54 0.0283
2-Hydroxybutyrate (AHB) Cysteine, methionine, SAM, taurine
metabolism
0.81 0.6720.99 0.0380
Indolebutyrate Tryptophan metabolism 1.22 1.0021.48 0.0445
Xenobiotics
Homostachydrine Food component/plant 0.81 0.6720.99 0.0380 0.46
Propyl-4-hydroxybenzoate sulfate Benzoate metabolism 0.79 0.6320.99 0.0406
S-(3-hydroxypropyl)mercapturic acid (HPMA) Chemical 0.81 0.6620.99 0.0417
Nucleotides
2’-Deoxyuridine Pyrimidine metabolism, uracil containing 1.42 1.0921.85 0.0084 0.48
1The odds ratio per 1 standard deviation increase in metabolite level.
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originally proposed by Warburg several decades ago.19 More
recently, laboratory studies support some degree of functional
TCA cycle and electron transport-oxidative phosphorylation
production of ATP in malignancies.20 Fatty acids from de
novo biosynthesis or through monoacylglycerol or diacylglyc-
erol lipase activity—reported to be overexpressed in aggres-
sive but not nonaggressive prostate cancers15,17,21,22—provide
a key molecular source of acetyl-CoA (beyond pyruvate from
glycolysis) through successive two-carbon beta-oxidation in
mitochondria.16,17 This is facilitated by carnitine palmitoyl
transferase-1 transport of fatty acids into the mitochondrial
matrix, including specifically in prostate cancer.23 Acetyl-CoA
then enters the TCA cycle via citrate synthase and oxaloace-
tic acid to yield citrate. These additional cellular perturba-
tions of fatty acid metabolism involving LCFAs, acetyl-CoA
and citrate provide energy and other macromolecules for
malignant cell proliferation and tumor anabolic requirements
and they potentially account for the lower lipid metabolite
profiles in the prostate cancer cases.
Beyond energy and anabolic requirements, altered lipid
regulation also supports membrane macromolecular species
needed during rapid cell proliferation, including for lipid rafts
and other key signaling constituents.24,25 Consistent with this,
we identified a large number of glycerophospholipids (includ-
ing monoacyl- and diacyl- glycerophosphoinositols, -glycero-
phosphoethanolamines and -glycerophosphocholines), LCFA,
PUFA and erucoyl-sphingomyelin among the top metabolites
associated with aggressive prostate cancer, with the phospho-
rylated derivative of myo-inositol, inositol-1-phosphate or
I1P, ranking highest. I1P is a member of the phosphatidyli-
nositide family of compounds that have become increasingly
recognized as integral plasma membrane, protein phosphoryl-
ation and second messenger signaling components.26 I1P and
related IP species such as IP4,5 (i.e., phosphorylated at car-
bons 4 and 5 of the inositol ring) are functionally related to
the numerous diacylglycerophospoinositol lipid metabolites
we found associated with aggressive prostate cancer. These
compounds serve as substrates for plasma membrane phos-
pholipase C that produces, (i) IP1,4,5 which is released into
the cytosol where it mobilizes ionized calcium from endo-
plasmic reticulum and (ii) diacylglycerol, which remains
membrane-associated to transactivate protein kinase C.15,18,27
Triggered by plasma membrane hormone receptor binding
and related to prostate cancer aggressiveness, both IP1,4,5 and
diacylglycerol can therefore serve as second messengers for
signal transduction through protein phosphorylation.21,27,28
Similar in association strength to our finding for alpha-
ketoglutarate, but independent of it, we found lower risk of
aggressive prostate cancer in men with higher serum citrate
status. Citrate is concentrated in the normal prostate periph-
eral zone glandular epithelium owing to high zinc ion con-
centration inhibition of mitochondrial aconitase conversion
Table 3. Serum metabolites associated with nonaggressive prostate cancer (p<0.05)
Metabolite Subpathway
Odds
ratio1 95% CI p-Value
p for
chemical
class
Lipids
11-Dehydrocorticosterone Sterol/steroid 0.62 0.4420.88 0.0069 0.66
21-Hydroxypregnenolone monosulfate Sterol/steroid 1.46 1.0322.06 0.0344
Glycerol 3-phosphate (G3P) Glycerolipid metabolism 0.70 0.5120.98 0.0391
Amino Acids
N-acetyl-3-methylhistidine Histidine metabolism 1.52 1.1422.02 0.0048 0.33
N-acetylleucine Valine, leucine and isoleucine metabolism 1.37 1.0221.85 0.0379
Beta-hydroxyisovalerate Valine, leucine and isoleucine metabolism 1.38 1.0121.89 0.0419
Indolepropionate Tryptophan metabolism 1.36 1.0021.85 0.0498
Xenobiotics
Cotinine Tobacco metabolite 0.59 0.3820.90 0.0140 0.27
Hydroxycotinine Tobacco metabolite 0.67 0.4720.96 0.0291
Saccharin Food component/plant 0.70 0.5020.98 0.0354
Nucleotides
2’-Deoxyuridine Pyrimidine metabolism, uracil containing 1.81 1.1522.85 0.0105 0.26
Adenosine 5’-monophosphate (AMP) Purine metabolism, adenine containing 1.50 1.0322.16 0.0328
Dihydroorotate Pyrimidine metabolism, orotate containing 1.36 1.0121.83 0.0401
Cofactors and Vitamins
L-Urobilin Hemoglobin and porphyrin metabolism 1.45 1.0322.04 0.0321 0.30
1The odds ratio per 1 standard deviation increase in metabolite level.
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Table 4. Metabolites associated with aggressive prostate cancer (p<0.05).
Metabolite Subpathway
Odds
ratio1 95% CI p-Value
p for
chemical class
Energy
Alpha-ketoglutarate TCA/Krebs cycle 0.69 0.5120.94 0.0201 0.018
Citrate TCA/Krebs cycle 0.69 0.5020.95 0.0220
Lipids
Inositol-1-phosphate (I1P) Inositol metabolism 0.56 0.3920.81 0.0024 0.041
Oleoyl-linoleoyl-glycerophosphoinositol Glycerophospholipid 0.64 0.4720.87 0.0042
Stearate (18:0) LCFA 0.65 0.4720.90 0.0102
Docosadienoate (22:2n6) LCFA; polyunsaturated fatty acid 0.66 0.4820.92 0.0141
3-Hydroxylaurate Fatty acid, monohydroxy 0.70 0.5220.94 0.0162
Margarate (17:0) LCFA 0.67 0.4820.93 0.0185
Linoleate (18:2n6) Essential fatty acid;
polyunsaturated fatty acid
0.68 0.4920.94 0.0204
Erucoyl-sphingomyelin Sphingolipid metabolism 1.53 1.0722.20 0.0205
Palmitoyl-linoleoyl-
glycerophosphoinositol
Glycerophospholipid 0.68 0.4920.95 0.0220
Laurate (12:0) MCFA 0.70 0.5120.95 0.0230
Dihomo-linoleate (20:2n6) LCFA; polyunsaturated fatty acid 0.71 0.5220.95 0.0232
1-Stearoylglycerophosphoglycerol Glycerophospholipid 0.69 0.5020.95 0.0245
16-Hydroxypalmitate Fatty acid, monohydroxy 0.71 0.5320.97 0.0288
Stearoyl-linoleoyl-
glycerophosphoethanolamine
Glycerophospholipid 0.72 0.5320.97 0.0308
Nonadecanoate (19:0) LCFA 0.71 0.5120.97 0.0310
Palmitate (16:0) LCFA 0.69 0.5020.97 0.0310
Stearoyl-arachidonoyl-
glycerophosphoethanolamine
Glycerophospholipid 0.69 0.5020.97 0.0341
Trimethylamine N-oxide Glycerolipid metabolism;
phospholipid metabolism
1.36 1.0221.81 0.0389
1-Linoleoylglycerophosphoethanolamine Glycerophospholipid 0.73 0.5420.99 0.0401
17-Methylstearate Fatty acid, branched 0.72 0.5320.99 0.0417
1-Linoleoylglycerophosphoinositol Glycerophospholipid 0.74 0.5620.99 0.0436
Palmitoyl-linoleoyl-glycerophosphocholine Glycerophospholipid 0.74 0.5521.00 0.0487
1-Arachidonoylglycerophosphoethanolamine Glycerophospholipid 0.72 0.5221.00 0.0494
Amino Acids
3-Methylglutarylcarnitine Lysine metabolism 1.60 1.1322.28 0.0082 0.87
Thyroxine Phenylalainine and tyrosine
metabolism
1.65 1.0822.54 0.0216
Alpha-ketobutyrate Cystine, methionine, SAM,
taurine metabolism
0.69 0.5120.95 0.0232
4-Imidazoleacetate Histidine metabolism 1.40 1.0421.89 0.0272
Glutarate (pentanedioate) Lysine metabolism 0.75 0.5720.99 0.0435
Arginine Urea cycle; arginine and proline
metabolism
1.31 1.0021.72 0.0488
Xenobiotics
Salicyluric glucuronide Drug 0.65 0.4620.90 0.0109 0.87
Isoeugenol sulfate Food component/plant 1.38 1.0121.89 0.0410
Peptides
Gamma-glutamylhistidine Gamma-glutamyl amino acid 0.75 0.5621.00 0.0465 0.91
1The odds ratio per 1 standard deviation increase in metabolite level.
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of citrate to isocitrate.29 In turn, citrate is secreted in prostatic
fluid in high concentration, a process referred to as “net citrate
production”,29 possibly to maintain a lower semen pH or pro-
vide an energy source for sperm motility or oocyte fertiliza-
tion. BPH tissue also exhibits elevated citrate content.30,31 By
contrast, malignant prostate cells exhibit low zinc and low
citrate concentrations, apparently the result of a biochemical
shift to citrate oxidation (along with alpha-ketoglutarate)
through the TCA cycle to provide greater ATP production for
tumor cell anabolism and proliferation. Such a metabolic
transformation of malignant prostate cells could account for
our finding of lower citrate status in aggressive cases versus
noncases and be reflective of the higher tumor energy require-
ments. Alternatively, tumor cell conversion of alpha-
ketoglutarate to citrate through “reductive carboxylation” as a
result of isocitrate dehydrogenase isoforms and NADP1/
NADPH, with subsequent acetyl-CoA formation and fatty acid
synthesis, has also been suggested in the setting of mitochon-
drial dysregulation.32 Citrate and alpha-ketoglutarate might
also be metabolized to biosynthetic precursors for fatty acids
and sterols (citrate) and glutamate (alpha-ketoglutarate). It is
also relevant and of interest that recently developed prostate
cancer magnetic resonance spectroscopic metabolic imaging
includes targeting decreased citrate as well as increased chol-
ine, creatine, polyamines and myo-inositol.30,31,33
Beyond the strong signals we detected for lipid and
energy metabolites, other specific metabolites appeared asso-
ciated with prostate cancer, including TMAO and thyroxine
for aggressive disease. The choline derivative TMAO has
been linked to atherosclerosis and cardiovascular disease,34
and most recently to elevated colorectal cancer risk.35 Given
the role of intestinal microbiota in human TMAO produc-
tion and the potential for local luminal epithelial effects, the
higher risk for prostate cancer suggested here deserves fur-
ther study. Thyroid hormone status has been previously
associated with prostate cancer, including in a recent study
from the ATBC cohort showing lower risk for hypothyroid
men.36 The positive associations between some nucleotides,
including AMP and nonaggressive disease (chemical class p-
value5 0.03) require reevaluation in other studies, particu-
larly given the number of known metabolites examined.
That the branched-chain amino acids did not show positive
associations with prostate cancer similar to those observed
for pancreatic cancer14 supports the likelihood that organ
site differences in metabolomic changes reflect underlying
tissue-specific biological changes that should be further
investigated.
Our study has several important strengths, primary among
which are: (i) having up to two decades between blood sam-
pling and prostate cancer diagnosis, (ii) analysis of serum
collected after an overnight fast and (iii) complete, popula-
tion registry-based case ascertainment. Long follow-up
affords us the opportunity to examine reverse causality and
possible temporal changes in circulating metabolites ranging
from up to 20 years before clinical diagnosis to within 10
years. Qualitative differences in lipid subclasses based on
time from blood collection to diagnosis were detected (e.g.,
fatty acids vs. glyceropholipids) and these patterns may pro-
vide biologically based leads regarding transformations during
prostate cancer development and progression. Fasting serum
should in theory reduce metabolite variation related to recent
food consumption and may offer a snapshot of “basal”
metabolomic profiles less influenced by recent food/beverage
consumption. Prostate cancers were for the most part diag-
nosed clinically and not from population PSA screening. The
high-quality laboratory platform provided low operational
variation in metabolite detection. Study limitations include
the relatively homogeneous population (i.e., Finnish smokers
of five or more cigarettes daily who were of Caucasian
descent) and modest sample size. Whether our findings for
cotinine and hydroxycotinine in nonaggressive prostate can-
cer were influenced by metabolite changes related to tobacco
smoking is possible but unlikely given that all cases and con-
trols were smokers at the time of serum collection and those
compounds are but two of several known tobacco-related
metabolites.37 Further, our results were unchanged when
adjusting for cigarettes smoked per day and were similar for
lighter and heavier smokers, suggesting that cigarette smok-
ing did not strongly influence the results. Given that we iden-
tified 626 known biochemicals, the findings for some of the
metabolites may be due to chance.
How the numerous metabolites identified in the present
study might biologically impact prostate cancer risk or relate
to known biochemical changes during its development and
progression can only be speculated. The specificity and sub-
pathway interrelatedness of the metabolites we identified are
compelling in light of well-established metabolic changes in
prostate malignancies, however. To our knowledge, alpha-
ketoglutarate, citrate, I1P and most of the other metabolites
we found associated with aggressive prostate cancer have not
been similarly examined in epidemiologic studies to date.
Lipid-lowering statin use is associated with lower risk of
aggressive prostate cancer38,39 and a recent meta-analysis of
cohorts with an average follow-up of five years found that
lower plasma/serum stearic acid and higher eicosapentaenoic
and docosapentaenoic acid concentrations, were related to
higher risk (with no other fatty acid or phospholipid associa-
tions).40 The case-control differences in the circulating
metabolites we observed were present up to 20 years before
clinical diagnosis. Given the widely accepted pathobiology of
latent, slow-growing, sub-clinical prostate cancers that is sup-
ported by autopsy studies41 and registry analyses,42 our find-
ings for aggressive disease could be interpreted as reflecting
the impact of metabolic changes in larger and disseminated
malignancies on circulating metabolites. Serum-tissue correla-
tive studies would be useful in this regard. Alternatively,
greater availability of lipid and energy metabolites in circula-
tion resulting from lifestyle exposures or genetic predisposi-
tion may inhibit the initiation or growth of prostate cancers.
It remains unclear whether the magnitude of the differences
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we observed in metabolite signals between cases and controls
would be sufficient to affect prostate cancer growth or initia-
tion. Additional basic and clinical research should address
the questions raised by these data.
In conclusion, our prospective study data indicate that
several circulating glycerophospholipid, fatty acid, energy
and related metabolites are inversely associated with
aggressive prostate cancer up to 20 years prior to diagnosis.
The findings may provide valuable and timely prospective
human validation of substantial prior basic and clinical
research relevant to lipid and energy metabolic transforma-
tions during prostate carcinogenesis. Further replication in
other prospective studies, including, where possible, metab-
olomic profiling of serial pre-diagnostic blood samples and
in prostate tissue (tumor and adjacent normal), will be
informative.
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